Drugs / Tecogalan
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00002136 | — | HIV infectious disease, Kaposi's sarcoma | Daiichi Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00002342 | — | HIV infectious disease, Kaposi's sarcoma | Daiichi Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00002138 | — | HIV infectious disease, Kaposi's sarcoma | Daiichi Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tecogalan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002136 ↗ |
| Known as | DS-4152 | “To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.” NCT00002138 ↗ |
| Known as | Tecogalan sodium | “To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.” NCT00002138 ↗ |
| Route | Intravenous | “Patients receive intravenous DS-4152 by infusion” NCT00002136 ↗ |